Model-based treatment optimization of a novel VEGFR inhibitor

British Journal of Clinical Pharmacology

Volumn 74, Issue 2, 2012, Pages 315-326

  Keizer, Ron J ^a   Gupta, Anubha ^b   Shumaker, Robert ^c   Beijnen, Jos H ^a,d   Schellens, Jan H M ^a,d   Huitema, Alwin D R ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b EISAI CO LTD   (Japan)

^c EISAI INC   (United States)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Hypertension; Lenvatinib; Modelling and simulation; Oncology; Pharmacodynamics; Proteinuria

Indexed keywords

ANTIHYPERTENSIVE AGENT; LENVATINIB;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EXPOSURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROCESS MODEL; PROCESS OPTIMIZATION; PROTEINURIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEINURIA; QUINOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84863732106     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04197.x     Document Type: Article

References (43)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34.
3. Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrell A-M, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 986-93.
4. Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, Laurent D, Dugan M, Steward WP. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 2003; 30 (3 Suppl. 6): 32-8.
5. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-93.
6. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23: 5474-83.
7. Glen H, Boss D, Evans TR, Roelvink M, Saro JM, Bezodis P, Copalu W, Das A, Crosswell G, Schellens JH. A phase I dose finding study of E7080 in patients (pts) with advanced malignancies. J Clin Oncol 2007; 25 (18 Suppl.): 14073 (Meeting Abstracts).
8. Maitland ML, Moshier K, Imperial J, Kasza KE, Karrison T, Elliott W, Undevia SD, Stadler W, Desai AA, Ratain MJ. Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway. J Clin Oncol 2006; 24 (18 Suppl.): 2035 (Meeting Abstracts).
9. Levy BI. Blood pressure as a potential biomarker of the efficacy of angiogenesis inhibitors. Ann Oncol 2009; 20: 200-3.
10. Lindauer A, Di Gion P, Kanefendt F, Tomalik-Scharte D, Kinzig M, Rodamer M, Dodos F, Sörgel F, Fuhr U, Jaehde U. Pharmacokinetic/Pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther 2010; 87: 601-8.
11. Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 2008; 98: 1633-40.
12. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard M-A, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon F-X. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496-9.
13. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
14. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935-42.
15. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 4022-8.
16. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2009; 66: 357-71.
17. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor ICA, Lynch M, Wilhelm S. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59: 561-74.
18. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-8.
19. Hidalgo M. Erlotinib: preclinical investigations. Oncology (Huntingt) 2003; 11 (Suppl. 12): 11-6.
20. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, Morin MJ. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291: 739-48.
21. Sleijfer S, Wiemer E. Dose selection in phase I studies: why we should always go for the top. J Clin Oncol 2008; 26: 1576-8.
22. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008; 122: 664-71.
23. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008; 14: 5459-65.
24. Yamada K, Hirata T, Fujiwara Y, Nokihara H, Yamamoto N, Yamada Y, Koizumi F, Nishio K, Koyama N, Tamura T. Phase I dose escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. J Clin Oncol 2008; 26 (15 Suppl.): 3527 (Meeting Abstracts).
25. Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, Koizumi F, Nishio K, Koyama N, Tamura T. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 2011; 17: 2528-37.
26. Gild ML, Bullock M, Robinson BG, Clifton-Bligh R. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011; 7: 617-24.
27. Sherman SI, Jarzab B, Cabanillas ME, Licitra LF, Pacini F, Martins R, Robinson B, Ball D, McCaffrey J, Shah MH, Bodenner D, Allison R, Newbold K, Elisei R, O'Brien J, Schlumberger M. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 2011; 29 (abstr 5503).
28. Keizer RJ, Gupta A, Mac Gillavry MR, Jansen M, Wanders J, Beijnen JH, Schellens JHM, Karlsson MO, Huitema ADR. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn 2010; 37: 347-63.
29. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR, Folkman J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61: 7669-74.
30. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-39.
31. Keizer R, Gupta A, Jansen M, Wanders J, Beijnen J, Schellens J, Karlsson M, Huitema A. Modeling of hypertension in response to anti-angiogenic therapy. 2009; PAGE 18 (2009) Abstr 1467. Available at (last accessed 1 May 2010).
32. Hong D, Koetz B, Kurzrock R, Senzer N, Hanekom W, Naing A, Wheler J, Mink J, Ren M, Nemunaitis J. Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors. J Clin Oncol 2010; 28: 7s (Suppl.; abstr 2540).
33. Karlsson M, Holford N. A tutorial on visual predictive checks. Abstracts of the Annual Meeting of the Population Approach Group in Europe (Internet). Marseille; 2008. Available at (last accessed 1 May 2010).
34. Brendel K, Comets E, Mentre F. Normalised prediction distribution errors for the evaluation of nonlinearmixed-effects models. Copenhagen: Abstracts of the Annual Meeting of the Population Approach Group in Europe, 2007. Available at (last accessed 1 May 2010).
35. NCI. Common Terminology Criteria for Adverse Events. 3.0 ed. 2006.
36. Beal SL, Sheiner LB. NONMEM Users Guides, eds Beal SL, Sheiner LB. Ellicott City, MD: Icon Development Solutions, 1989.
37. Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 2011; 101: 72-9.
38. De Stefano A, Cannella L, Carlomagno C, Crispo A, Bianco R, Marciano R, Pepe S, De Placido S. Correlation between bevacizumab-related hypertension and response in mCRC patients. J Clin Oncol 2010; 28: 7s (Suppl.; abstr 3581).
39. Radaideh S, Gerber D, Dunphy F, Yan J, Xie Y, Fenske E, Shouldis J, Kindler H, Dowell J. Association of hypertension (HTN) and clinical outcome in a phase II trial of cisplatin (C), pemetrexed (P), and bevacizumab (B) in patients (pts) with untreated malignant mesothelioma. J Clin Oncol 2010; 28 (Suppl.; abstr e18012).
40. Wilhelm K, Atkinson B, Khakoo A, Tannir N, Jonasch E. A retrospective evaluation of antiangiogenic therapy induced hypertension in metastatic renal cell carcinoma. J Clin Oncol 2010; 28 (Suppl.; abstr e15047).
41. Kim R, Byrne M, Hammel J, El-Gazzaz G, Aucejo F. Association of hypertension with overall outcome in patients taking sorafenib in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2010; 28 (Suppl.; abstr e14536).
42. Hurwitz H, Douglas P, Middleton J, Sledge G, Johnson D, Reardon D, Chen D, Rosen O. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). J Clin Oncol 2010; 28: 7s (Suppl.; abstr 3039).
43. Gupta A, Koetz B, Hanekom W, O'Brien JP, Wanders J, Jansen M. 453 Population pharmacokinetics (PK) and exposure/response relationships of the receptor tyrosine kinase inhibitor E7080 in phase I studies. Eur J Cancer Suppl 2010; 8: 143.